Stifel maintains a Hold rating and $87 price target on Medtronic (MDT) shares. The Centers for Medicare & Medicaid Services’ initial proposal for renal denervation reimbursement “seems positive,” with a final decision expected by October 8, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic’s Renal Denervation Opportunity: Hold Rating Amid Challenges and Potential Growth
- Medtronic’s Market Position: Balancing Growth Opportunities and Challenges
- Medtronic Positioned for Growth with Favorable CMS Decision on Renal Denervation
- Buy Rating Affirmed for Medtronic Amid Favorable NCD Proposal and RDN Market Growth
- Medtronic’s Mid-Q Response Study: A New Chapter in Cardiac Care